Degeneration of dopamine neurons in the substantia nigra and intracellular deposition of Lewy body inclusions are the pathologic hallmarks of Parkinson disease (PD). Depletion of dopamine and other neurotransmitters results in motor (rest tremor, bradykinesia, and rigidity) and nonmotor (cognitive impairment, sleep disorders, fatigue, and depression) symptoms.
Advances with MRI in Parkinson disease
From freezing to festination Degeneration of dopamine neurons in the substantia nigra and intracellular deposition of Lewy body inclusions are the pathologic hallmarks of Parkinson disease (PD). Depletion of dopamine and other neurotransmitters results in motor (rest tremor, bradykinesia, and rigidity) and nonmotor (cognitive impairment, sleep disorders, fatigue, and depression) symptoms.
Distinguishing idiopathic PD from other parkinsonian syndromes can be challenging at clinical onset, but is critical for establishing adequate prognosis and treatment. Although metrics derived from conventional MRI are useful to exclude atypical syndromes or secondary parkinsonism (e.g., tumors, Wilson disease, manganism, and hydrocephalus), no "positive" MRI markers of idiopathic PD are available. Thus, in contrast to the rapid imaging advances in multiple sclerosis or Alzheimer disease (AD), MRI in PD underwent a long "freezing" period.
Advanced MRI techniques are providing novel approaches. Ultra-high-field scanners (7.0 T or greater) and quantitative MRI techniques, including diffusion tensor MRI and susceptibility-weighted imaging, hold substantial promise for an accurate quantification of tissue injury in the substantia nigra 1,2 and other involved brain areas. Combined with sophisticated postprocessing, such as voxel-wise mapping and tractography, these techniques are contributing to the characterization of in vivo pathologic substrates of the clinical manifestations of PD. For instance, freezing of gait was associated with damage of a frontoparietal cortical network, 3 and structural abnormalities 4 of locomotor mesencephalic regions. Depression in PD has been correlated with atrophy of white matter regions of the cortical-limbic network. 5 Cognitive impairment is one of the most disabling symptoms of PD, with overt dementia increasing exponentially with age. 6 In contrast to other dementing conditions in which gray matter (GM) atrophy is largely correlated with cognitive decline, in PD GM atrophy is typically modest and not clearly associated with cognitive deficits. Of note, it is the extent of white matter damage that is correlated with the global cognitive status of these patients. 7 The study by Tessitore et al. 8 in this issue of Neurology ® illustrates how a clever study design and the use of novel MRI techniques can contribute substantively to the advancement of our understanding of cognitive deficits in PD. In cognitively unimpaired patients with PD, the authors interrogated the functional connectivity (FC) at rest of the default mode network (DMN), a medial cortical network involving several regions located in the fronto-parietal-temporal lobes and cingulum. 9 Although the DMN is not unique in exhibiting coherent fluctuations of spontaneous brain activity at rest, it is unique in its response (a decrease in activity) to cognitive tasks. DMN FC decreases with aging 9 and in a variety of neuropsychiatric and neurologic disorders. 9 This study demonstrated that the FC of the posterior regions of the DMN is also reduced in PD and correlates with neuropsychological performance. As expected, no GM atrophy was found, suggesting that functional changes may precede structural abnormalities to the cortex and deep nuclei.
Although limited by the relatively small number of patients and by their clinical homogeneity, this study suggests that assessing DMN FC can be a rewarding exercise for the early detection of cognitive impairment in PD. Even more important, this study extends the field of research based on MRI technology in idiopathic PD, which is thereby moving from "freezing" to "festination."
The main unanswered question is whether the observed functional abnormalities are sensitive to the progression of PD cognitive deficits and have a role in the prediction of the risk of developing dementia. Interestingly, the present findings concur with the notion that damage and dysfunction of temporal and posterior brain structures can contribute to the severity of cognitive impairment in PD in addition to the characteristic dysexecutive syndrome. Future research in patients with PD with cognitive impairment or the longitudinal re-evaluation of the present cohort might help to clarify this issue.
At present, there is an urgent need to identify early biomarkers of PD to monitor its evolution and response to treatment, and to select patients to be enrolled in clinical trials. PET and SPECT ligands are valuable in the detection of dopamine neuron terminal dysfunction in both patients with PD and subjects at high risk for developing parkinsonian syndromes. Metrics derived from these techniques correlate with the degree of PD motor disability and are useful for monitoring disease progression. 10 However, altered nondopaminergic neurotransmission is likely to play a role in the nonmotor symptoms of these patients, including cognitive impairment. Although this can be examined using appropriate radiotracers, nuclear medicine methods have inherent limitations, including safety (especially in case of serial acquisitions), long acquisition times, and a low temporal and spatial resolution. As a consequence, even if it provides only an indirect measure of neuronal activity, fMRI has unquestionable advantages, including its noninvasiveness, widespread availability, and better temporal and spatial resolution.
The study by Tessitore et al. 8 indicates that DMN dysfunction in PD may occur prior to clinical evidence of cognitive impairment. In agreement with what has been shown in patients with early AD, 9 this suggests a vulnerability of the posterior cortical regions of the human DMN to aging and different neurodegenerative conditions. Whether such vulnerability generically predisposes to cognitive dysfunction or is associated with specific neuropathologic processes should be investigated further. Other important but still unexplored issues are whether FC abnormalities early in the course of PD are restricted to the DMN or involve other cognitive-related networks, whether such functional abnormalities are driven or influenced by structural damage to "critical" white matter fiber bundles, and whether different combinations of these abnormalities may predict different patterns of cognitive decline. 
